Investigational drug · Phase 2
TT-01488
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mantle Cell Lymphoma (MCL).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "TT-01488"
First trial start
2026
Oct 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TT-01488", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mantle Cell Lymphoma (MCL)
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TT-01488" as an intervention, largest first.
- A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell LymphomaNot yet recruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT07855016 · 188 participants (planned) · Start Oct 10, 2026 · Primary completion Oct 10, 2029
Drug: TT-01488 Tablets; Rituximab and 2 more · For: Mantle Cell Lymphoma (MCL)
Sites: Guangzhou, China; Shanghai, China
- Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesStatus unknown
TransThera Sciences (Nanjing), Inc.Industry
NCT05275504 · 37 participants (planned) · Start Jun 2022 · Primary completion Sep 2022
Drug: TT-01488 · For: B-Cell Malignancies
Sites: Canton, Ohio; Houston, Texas
TransThera Sciences (Nanjing), Inc.Industry
NCT05683717 · 37 participants (planned) · Start Mar 30, 2023 · Primary completion Oct 31, 2026
Drug: TT-01488 Tablets · For: B-Cell Malignancies
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Mantle Cell Lymphoma (MCL)
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
- zamtocabtagene autoleucelMB-CART2019.1Phase 25 trials
Miltenyi Biomedicine GmbH · CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis
- LacutoclaxPhase 22 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.